Biopharma companies develop medicines, vaccines and advanced therapies to prevent, treat and manage disease. The sector spans drug discovery, clinical development, manufacturing and commercialisation across a wide range of therapeutic areas.
This category includes companies working on:
Browse 304 UK biopharma companies below.
Global biopharma with major UK R&D and regulatory operations
Pfizer Limited is the principal UK subsidiary of Pfizer Inc., one of the world's largest biopharmaceutical companies. Its Sandwich, Kent site houses pharmaceutical sciences, global clinical supplies, quality assurance, and worldwide safety and regulatory operations serving over 175 markets. A Devices Centre of…
Small molecule MMR inhibitors to enhance tumour immunogenicity
NeoPhore is a UK immuno-oncology company developing first-in-class small molecule inhibitors of the DNA mismatch repair pathway. By transiently blocking MMR, the company's compounds render tumours MMR-deficient and immunogenic, generating neoantigens that stimulate immune responses against cancer. The approach aims to…
European specialty pharma focused on gastroenterology and hepatology
Norgine is a European specialty pharmaceutical company developing, manufacturing, and commercialising medicines across gastroenterology, hepatology, and cancer supportive care. Founded in 1906 and privately owned, the company markets a portfolio of specialty pharmaceutical products and medical devices across Europe,…
Global licensing and commercialisation of established branded pharmaceutical medicines
Pharmanovia is a specialty pharmaceutical company that acquires, licenses and commercialises established branded medicines, extending their lifecycle for patients worldwide. The company's portfolio spans more than 25 medicines across endocrinology, neurology, cardiovascular and oncology, built through strategic…
Inhaled therapies for COPD and chronic respiratory diseases
Verona Pharma is a biopharmaceutical company developing and commercialising inhaled therapies for chronic respiratory diseases. Its lead product, ensifentrine, is a first-in-class dual inhibitor of PDE3 and PDE4 that combines bronchodilator and non-steroidal anti-inflammatory activity in a single inhaled compound.…
Immunometabolism drugs for autoimmune and inflammatory diseases
Istesso is a drug discovery and development company working in immunometabolism, developing oral small molecule therapies that reprogram cellular metabolism to treat autoimmune and inflammatory conditions. Its lead candidate is a first-in-class metabolic reprogramming agent for rheumatoid arthritis with a dual…
Clinical-stage biopharma improving nucleoside analogue chemotherapy efficacy
NuCana is a clinical-stage biopharmaceutical company developing a pipeline of cancer medicines using proprietary phosphoramidate prodrug chemistry. Its approach transforms established nucleoside analogue chemotherapy agents into modified forms that bypass key tumour resistance mechanisms, delivering higher…
AI-guided personalised mRNA cancer vaccine development
Genevation is a biotechnology company developing personalised mRNA cancer vaccines using AI-assisted tumour neoantigen identification. Its platform analyses tumour sequencing data to select patient-specific targets and combines computational vaccine design with cell-free RNA manufacturing. The company reports…
Cell-based regenerative therapies for heart failure
Cardiogeni is a clinical-stage biotechnology group developing regenerative cell medicines for cardiovascular disease. Its lead programme, CLXR-001, uses engineered immunomodulatory progenitor cells intended to support repair of damaged heart tissue in patients with heart failure. The group is progressing plans for…
Carbohydrate binding molecules targeting the tumour glycome in cancer
Omideon is a Scottish preclinical biotechnology company applying multivalent carbohydrate binding molecule (mCBM) technology to oncology. Spun out from Pneumagen Limited by demerger in 2020, the company uses genetic engineering to develop mCBMs with high affinity for tumour-associated terminal glycans. Its lead…
KnotBody therapeutics for ion channel and GPCR diseases
Maxion Therapeutics is a biotechnology company developing a pipeline of KnotBody therapeutics for diseases driven by ion channel and G protein-coupled receptor dysfunction. The platform combines naturally occurring mini-proteins with antibodies to generate potent, selective and long-acting biologics against target…
Biological medicines and vaccine manufacturing at Porton Down
Porton Biopharma is a government-owned biopharmaceutical company based at Porton Down, Wiltshire. It developed and manufactured biological medicines using microbial fermentation, including the UK's anthrax vaccine and Erwinase (crisantaspase), an enzyme therapy for acute lymphoblastic leukaemia. In March 2025, the…
AI-driven T-cell receptor discovery platform for solid tumour immunotherapies
Exogene is an Oxford biotech developing TCR-based immunotherapies for solid tumours. Its platform integrates generative AI, biophysical simulation, and high-throughput TCR-antigen screening to identify rare, high-affinity cancer-specific T-cell receptors from patient tumour samples. The company develops TCR-T cell…
Single-pill fixed-dose combinations for cardiometabolic disease
George Medicines is a late-stage biopharmaceutical company developing innovative single-pill, fixed-dose combination therapies for cardiometabolic diseases. Rather than pursuing early drug discovery, the company reformulates established best-in-class small molecules into novel proprietary low-dose combinations…
TSG-6 protein therapeutics for inflammatory and degenerative disease
Link Biologics is a preclinical-stage biotechnology company developing protein therapeutics based on TSG-6, an endogenous human protein with anti-inflammatory and tissue-protective properties. Spun out from the University of Manchester in 2021, the company is advancing its lead asset, Link_TSG6, across programmes in…
Generics pharmaceutical manufacturing, packaging and IP development for global markets
Noumed Life Sciences is a generics pharmaceutical manufacturing company developing IP and manufacturing products for a range of therapeutics. The company's MHRA-accredited facility provides manufacturing, packaging, quality control, testing and logistics services, supporting multiple multinational partners alongside a…
CreaTap antibody engineering for improved solid tumour penetration
Creasallis is a biotechnology company developing antibody engineering technologies intended to improve drug delivery into solid tumours. Its patented CreaTap platform modifies therapeutic antibodies to promote deeper penetration into tumour tissue. The approach is under development for monoclonal antibodies,…
British generic medicine manufacturer supplying UK and European healthcare markets
Bristol Laboratories is a British pharmaceutical company developing, manufacturing, marketing and distributing generic medicines across the UK and Europe. The company manufactures a wide range of pharmaceutical products spanning urology, pain relief, antibiotics and respiratory conditions, alongside an expanding…
Deep learning platform for small molecule drug discovery
CHARM Therapeutics is a clinical-stage biotechnology company applying 3D deep learning to small molecule drug discovery. Its proprietary platform uses protein-ligand co-folding algorithms to predict binding interactions and identify candidates against difficult-to-drug targets. CHARM's pipeline focuses primarily on…
T cell-engaging multispecific antibody fragments for solid tumours
Crescendo Biologics is a clinical-stage biopharmaceutical company developing multispecific therapeutics based on fully human single-domain antibody fragments engineered for enhanced tumour penetration and selective T cell activation within the tumour microenvironment. Its lead programme is in Phase 1b clinical trials…